-
On Sept. 24, 2008, FDA approved a generic formulation of Didanosine (ddI) Delayed Release Capsules, 125 mg, 200 mg, 250 mg, and 400 mg, manufactured by Aurobindo Pharma Limited, Hyberdad, India. Didanosine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI), which helps keep HIV, the virus that causes AIDS, from reproducing, and is intended to be used with other anti-retroviral agents for the treatment of HIV-1 infection.
-
Just-presented research at the XVII International AIDS Conference in Mexico City indicates that adult male circumcision continues to reduce the risk of acquiring HIV through heterosexual intercourse for at least 3.5 years.
-
Jackie Fairley, BVSc, BSc, MBA, chief executive officer of Starpharma of Victoria, Australia, recently fielded some questions from AIDS Alert about the company's investigational microbicide, VivaGel.®
-
As if HIV clinics and physicians didn't have enough government paperwork and bureaucracy to worry about, the nearly three-year-old Medicare Part D prescription drug coverage offers a labyrinth of obstacles, pitfalls, and other problems in keeping HIV patients adherent to their antiretroviral treatment (ART).
-
Some of the concerns and predictions HIV/AIDS advocates made two years ago about the impact of Medicare Part Dthe prescription drug benefiton HIV antiretroviral treatment appear to be coming true.
-
-
Increased migraine attack frequency and overuse of acute medication, especially barbiturates and opiates, are risk factors for the chronification of migraine, which occurs in up to 2% of individuals.
-
The Babinski sign continues to be a valid bed-side test for pyramidal tract lesions.
-
A randomized, controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Perhaps the most prominent cardiovascular report in 2007 was the publication of the COURAGE trial (N Engl J Med. 2007;356:1503-1516), which demonstrated the equality in major CV outcomes in randomized patients with stable CAD, most with angina, who were assigned PCI with optimal medical therapy (OMT) vs OMT alone, with a mean follow-up of 4.6 years.